NCT01489813 2025-02-05
Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment
Emory University
Phase 2 Completed
Clinical Trials
9 trialsNCT02624388 2024-05-06
UVA-Gen001
University of Virginia
Phase 2 Terminated
NCT02766478 2022-09-27
GeniPro
Emory University
Phase 2 Terminated
NCT00118040 2021-06-10
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00769990 2017-12-13
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT00058266 2012-07-19
Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy
Northwestern University
Phase 2 Terminated
NCT00005827 2012-04-24
Genistein in Treating Patients With Stage II, Stage III, or Stage IV Prostate Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1 Withdrawn
NCT00546039 2008-09-30
Synthetic Genistein (BONISTEINâ„¢) in Patients Who Are Undergoing Surgery for Prostate Cancer
University Hospital, Aker
Phase 2 Unknown
NCT00001696 2008-03-04
A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor
National Institutes of Health Clinical Center (CC)
Phase 1 Completed